|
|
Volumn 2 Suppl 1, Issue , 2001, Pages
|
|
The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DOCETAXEL;
DOXORUBICIN;
PACLITAXEL;
TAXOID;
ADJUVANT CHEMOTHERAPY;
BREAST TUMOR;
CLINICAL TRIAL;
DECISION MAKING;
FEMALE;
HUMAN;
METHODOLOGY;
PROGNOSIS;
REVIEW;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS;
DECISION MAKING;
DOXORUBICIN;
FEMALE;
HUMANS;
PACLITAXEL;
PROGNOSIS;
RESEARCH DESIGN;
TAXOIDS;
MLCS;
MLOWN;
|
|
EID: 21544436870
PISSN: 15268209
EISSN: None
Source Type: Journal
DOI: 10.3816/cbc.2001.s.002 Document Type: Review |
|
Times cited : (6)
|
|
References (27)
|
